News >

CMV Vaccine Falls Short in Phase III Trial

Jason Harris
Published: Monday, Jan 22, 2018

Vijay Samant

Vijay Samant
ASP0113, an investigational DNA vaccine developed for cytomegalovirus (CMV)-seropositive hematopoietic stem cell transplant (HSCT) patients, has failed to meet its primary and secondary endpoints in results from the phase III HELIOS trial.1

In the phase II trial, the safety profiles were generally similar between treatment groups, but local injection site reactions were more common in the ASP0113 treatment group.

References

  1. Astellas and Vical Announce Top-Line Results for Phase 3 Trial of Cytomegalovirus Vaccine ASP0113 in Hematopoietic Stem Cell Transplant Recipients. Astellas Pharma Inc. and Vical Incorporated. Published and accessed January 18, 2018. https://www.astellas.com/en/corporate/news/pdf/eg_fin_180122.pdf.
  2. Vical and Astellas Announce Topline Results from a Phase 2 Study of Investigational Cytomegalovirus (CMV) Vaccine (ASP0113) in Kidney Transplant Patients. Astellas Pharma Inc. and Vical Incorporated. Published September 19, 2016. Accessed January 18, 2018. http://bit.ly/2n1MSwS.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: How Can We Optimize Outcomes in Head and Neck Cancers with Immunotherapeutic Strategies?Oct 31, 20191.5
The Patient and Provider Connection™: Effective Communication to Optimize the Diagnosis and Management of Irritable Bowel Syndrome and Chronic Idiopathic ConstipationOct 31, 20191.0
Publication Bottom Border
Border Publication
x